Longboard Pharmaceuticals, Inc. is a biopharmaceutical firm with a focus on developing medicines for neurological ailments. LP352 is the company's lead product candidate that's presently undergoing a Phase 1b/2a clinical trial to treat epilepsy-linked seizures. Longboard Pharmaceuticals, Inc. also has preclinical product candidates, including LP659 and LP143, which aim to treat multiple neurological conditions.